Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
Multiple Indications Cancer
DRUG: Dasatinib
Number of Participants Who Received Dasatinib Treatment, Number of participants who received dasatinib treatment for prostate cancer and chronic phase chronic myeloid leukemia who had also participated on prior protocols CA180-227, CA180-363 and CA180-056 investigating dasatinib. Dasatinib tablet administered once a day by mouth., From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)|Duration of Treatment, Duration of treatment for participants who received dasatinib treatment for prostate cancer and chronic phase chronic myeloid leukemia who had also participated on prior protocols CA180-227, CA180-363 and CA180-056 investigating dasatinib. Dasatinib tablet administered once a day by mouth., From first dose on this study (CA180-597) to last dose on this study (up to approximately 76 months)
Number of Participants With Adverse Events, Number of Participants with Adverse Events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug., From first dose on this study (CA180-597) to 30 days after last dose of study therapy (up to approximately 77 months)|Number of Participants With Serious Adverse Events, Number of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event., From first dose on this study (CA180-597) to 30 days after last dose of study therapy (up to approximately 77 months)
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.